Lv21
178 积分 2023-06-19 加入
Butyrophilin 3A (BTN3A, CD277)‐specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation
6小时前
待确认
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
7天前
已完结
Abstract LB056: The spatial landscape of progression and immunoediting in primary melanoma at single cell resolution
2个月前
已关闭
Abstract LB057: Pre-clinical characterization of IBI343, a site-specifically conjugated anti-Claundin18.2 ADC, for treating solid tumors
2个月前
已关闭
Abstract LB057: Pre-clinical characterization of IBI343, a site-specifically conjugated anti-Claundin18.2 ADC, for treating solid tumors
2个月前
已关闭
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
2个月前
已完结
Phase I Trial of 177 Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer
6个月前
已关闭
Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study
6个月前
已完结
A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer
6个月前
已完结
New Drug for Metastatic Castration-Resistant Prostate Cancer
6个月前
已完结
皖公网安备34019202002308
